In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS partners Sprycel and Ixempra with Otsuka

Executive Summary

In a ten-year agreement that takes effect in 2010, Bristol-Myers Squibb has partnered its leukemia treatment Sprycel (dasatinib) and advanced breast cancer drug Ixempra (ixabepilone) with Otsuka Pharmaceutical in the US, Europe, and Japan. The deal includes present and future indications of the products.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies